Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K. Takahama T, et al. Among authors: hirabayashi m. Oncotarget. 2016 Sep 6;7(36):58492-58499. doi: 10.18632/oncotarget.11303. Oncotarget. 2016. PMID: 27542267 Free PMC article.
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, Kagami R, Washio Y, Ishida T, Kogo M, Tomii K, Okuno T, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim YH, Miyakoshi C, Yoshimura K, Hirai T; Kyoto Thoracic Oncology Research Group (KTORG). Yokoyama T, et al. Among authors: hirabayashi m. Lung Cancer. 2019 Sep;135:175-180. doi: 10.1016/j.lungcan.2019.03.030. Epub 2019 Mar 28. Lung Cancer. 2019. PMID: 31446992 Clinical Trial.
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Fujimoto D, et al. Among authors: hirabayashi m. Lung Cancer. 2018 May;119:14-20. doi: 10.1016/j.lungcan.2018.02.017. Epub 2018 Mar 2. Lung Cancer. 2018. PMID: 29656747
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.
Ikeda S, Yoshioka H, Kaneda T, Yokoyama T, Niwa T, Sone N, Ishida T, Morita M, Tomioka H, Komaki C, Hirabayashi M, Hasegawa Y, Noguchi T, Nakano Y, Sakaguchi C, Yoshimura K, Hirai T. Ikeda S, et al. Among authors: hirabayashi m. Oncology. 2019;97(6):327-333. doi: 10.1159/000501967. Epub 2019 Aug 14. Oncology. 2019. PMID: 31412347 Clinical Trial.
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Fujimoto D, et al. Among authors: hirabayashi m. J Thorac Oncol. 2019 Mar;14(3):468-474. doi: 10.1016/j.jtho.2018.10.167. Epub 2018 Nov 20. J Thorac Oncol. 2019. PMID: 30468872 Free article.
Influence of loneliness and social isolation on the diagnosis and treatment of Japanese patients with advanced lung cancer: a prospective cohort study.
Takemura T, Kataoka Y, Shirakawa C, Okazaki K, Sakurai A, Imakita T, Ikegaki S, Matsumoto H, Saito E, Takata H, Kaku S, Wada N, Shinomiya M, Otoshi T, Shimada M, Nikaido J, Iki R, Hirano K, Hirai T, Endo K, Hirabayashi M, Naganuma T. Takemura T, et al. Among authors: hirabayashi m. Ann Palliat Med. 2021 Jun;10(6):6236-6246. doi: 10.21037/apm-21-402. Epub 2021 Jun 2. Ann Palliat Med. 2021. PMID: 34118842 Free article.
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M. Kim YH, et al. Among authors: hirabayashi m. Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30. Cancer Chemother Pharmacol. 2012. PMID: 22752216 Clinical Trial.
A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.
Yoshida H, Kim YH, Sakamori Y, Nagai H, Ozasa H, Kaneda T, Yoshioka H, Nakagawa H, Tomii K, Okada A, Yoshimura K, Hirabayashi M, Hirai T. Yoshida H, et al. Among authors: hirabayashi m. Anticancer Res. 2020 May;40(5):2981-2987. doi: 10.21873/anticanres.14278. Anticancer Res. 2020. PMID: 32366452 Clinical Trial.
475 results